Co-mutation status and/or histology may influence response to combined PARP and immune checkpoint inhibition in SCLC, as one of the responders had a BRCA mutation that may have sensitized to PARP inhibition, and the other had EGFR-mutant transformed SCLC. Here, EGFR is linked to small cell lung carcinoma.